FDA Approves Merck's (MRK) First Oral PCSK9 Inhibitor, 'Lipfendra,' for Hypercholesterolemia Treatment
Merck's Game Changer: First Oral PCSK9 Inhibitor Approved
The U.S. Food and Drug Administration (FDA) has officially approved 'Lipfendra' (enlicitide), Merck & Co.'s (MRK) first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, for the treatment of hypercholesterolemia. Announced on July 16, 2026, this approval marks a historic milestone in transforming the existing hyperlipidemia treatment paradigm from injectable to oral administration. It strategically targets the unmet needs of patients who are reluctant to receive injections, aiming to disrupt the market.
Robust Efficacy Demonstrated Through CORALreef Phase 3 Data
Lipfendra has definitively proven its efficacy, comparable to existing injectable treatments, through the large-scale Phase 3 clinical trial program, 'CORALreef.' Specifically, in a clinical trial targeting hypercholesterolemia patients (CORALreef Lipids), it demonstrated a 56% reduction in low-density lipoprotein cholesterol (LDL-C) at week 24 compared to placebo. Furthermore, in a clinical trial targeting heterozygous familial hypercholesterolemia (HeFH) patients (CORALreef HeFH), it achieved an excellent cholesterol reduction rate of 59% compared to placebo, fully securing its clinical validity.
Shifting the Landscape of the Hyperlipidemia Market, Previously Dominated by Injectables
The existing PCSK9 inhibitor market has been dominated by large injectable drugs, such as Amgen's Repatha and Novartis' Leqvio, with an annual scale of approximately $3 billion. While these injectable treatments offer potent LDL-C lowering effects, they have clear limitations, including reluctance towards self-injection and the inconvenience of hospital visits. The introduction of Lipfendra, a once-daily 20mg oral tablet, is expected to significantly improve treatment adherence and transform the paradigm of chronic disease management.
Fierce Competition Among Big Pharma for a $23 Billion Market
The global PCSK9 inhibitor market is a key area projected to grow rapidly from $4.4 billion in 2025 to over $23 billion by 2035. With this Lipfendra approval, Merck aims to capture a significant share of the injectable treatment market and achieve peak annual sales of up to $5 billion. In response, AstraZeneca is conducting a Phase 2b trial of its oral pipeline candidate, AZD0780, and other latecomers are also intensifying their efforts, leading to a more competitive landscape for market leadership.
Final Gateway to Demonstrate Cardiovascular Benefits and Future Prospects
Merck is continuing a large-scale clinical trial (CORALreef Outcomes) to verify whether Lipfendra can not only improve LDL-C levels but also reduce the actual incidence of cardiovascular diseases. If it successfully obtains cardiovascular risk reduction (CVOT) data, Lipfendra will gain a strong impetus to potentially become the first-line standard of care for hyperlipidemia treatment. This innovation, which combines convenience and efficacy in the chronic disease area, provides a sustainable roadmap for the development of oral peptide drugs in the pharmaceutical and biotechnology industry.
This FDA approval serves as a direct catalyst for the rapid transformation of the $4.4 billion PCSK9 inhibitor market, projected to reach $23 billion by 2035, from injectables to oral administration. With annual sales of $3 billion and $1.2 billion, respectively, for Amgen's Repatha and Novartis' Leqvio in 2025, Merck (MRK) aims to achieve peak annual sales of up to $5 billion by emphasizing improved treatment adherence. From a research and development perspective, the demonstration of up to 59% LDL-C reduction in the CORALreef Phase 3 trial will further accelerate the development of competing oral pipeline candidates, such as AstraZeneca's AZD0780 (Phase 2b). In the long term, the outcome of the ongoing large-scale cardiovascular outcomes trial (CORALreef Outcomes) will determine whether Lipfendra can establish itself as the first-line standard of care for hyperlipidemia, following statins.